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ABSTRACT
Objectives: About 20% of endometrial cancer (EC) patients have advanced disease (FIGO III & IV) at the moment of diag-
nosis. An attempt to evaluate the prognostic value of biochemical markers of inflammation and classic endometrial cancer 
prognostic factors in the group of advanced EC (aEC) patients has been made in this study.
Material and methods: Records of 266 patients treated in the Maria Sklodowska-Curie Memorial Cancer Centre and Insti-
tute of Oncology, Cracow Branch between the year 2006 and 2018 were included in the study. Follow-up ranged from 1 to 
138 months. Progression free survival (PFS) and overall survival (OS) have been set as endpoints. Tests such as: chi-squared, 
Fisher, log-rank, Mann-Whitney, Kruskal-Wallis and Cox proportional hazard ratio were used in the statistical analyses.
Results: In the analysed group high total platelet count (PLT) before operative treatment and high levels of white blood cells 
(WBC), PLT, neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) before adjuvant therapy (AT) have been 
significantly associated with shorter PFS and OS. After setting the cut-off values of NLR and PLR a statistically significant 
correlation between those parameters and PFS as well as OS has been shown. Multivariate analysis has indicated that NLR 
is an independent prognostic factor of the course of aEC. 
Conclusions: NLR and PLR correlate significantly with OS and PFS in aEC. NLR is an independent prognostic factor in this 
group. It is possible to distinguish 3 risk groups, among aEC patients, based on NRL and PLR.
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INTRODUCTION
Endometrial cancer (EC) is the most frequently diag-
nosed gynaecological malignancy in the developed coun-
tries. There is an upturn in morbidity especially among older 
women, in which group the treatment is the most difficult. 
Even though most endometrial cancer patients are diag-
nosed at an early stage of the disease, in 2016 in Poland 19% 
of the reported cases were advanced endometrial cancer 
(aEC) [1–3]. Advanced endometrial cancer patients require 
an individual approach on every stage of treatment. Due 
to healthcare system setup in Poland many aEC patients 
begin their treatment in district hospitals and are referred 
to cancer centres after surgery. The amount of information 
available from before treatment is in most cases scarce. In 
this setting any data of reliable prognostic significance, 
that can be obtained while planning adjuvant treatment 
is very valuable. 
The link between inflammation and carcinogenesis has 
been first described in the second half of 19th century. Cur-
rently two pathways connecting carcinogenesis with the 
immune system are distinguished: extrinsic, where chronic 
inflammation creates an environment favourable to carcino-
genesis and intrinsic, where cancer cells induce immunologic 
response favouring further development of the tumour [4–7]. 
The exact mechanisms underlying the interaction between 
coagulation, inflammation and carcinogenesis remain un-
clear. Neutrophils inhibit the immune system by suppressing 
T-type lymphocytes, and through secretion of various cy-
tokines, chemokines and growth factors they take part in the 
creation of tumour inducing microenvironment. It is said that 
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glycoproteins such as platelet-derived growth factor (PlGF), 
transforming growth factor beta (TGF-β) or vasculo-epithelial 
growth factor (VEGF) secreted by platelets play a similar role. 
This effect is amplified by increased platelet production and 
aggregation associated with cancer [8–11].
Among other markers derived from complete blood 
count (CBC), the predictive value of neutrophil/lymphocyte 
ratio (NLR) and platelet/lymphocyte ratio (PLR) has been as-
sessed for many types of tumours, such as breast, stomach, co-
lon or lung cancer. There is paucity of data on its significance 
in endometrial cancer. [12–15]. At present there are no papers 
on their prognostic value in advanced endometrial cancer.
Objectives
The aim of this study was to assess the prognostic value 
of NLR and PLR calculated at the stage AT planning in aEC 
patients and the potential utility of these markers in clini-
cal practice.
MATERIAL AND METHODS
Records of 266 patients treated in the Maria Sklodows-
ka-Curie Memorial Cancer Centre and Institute of Oncology, 
Cracow Branch between year 2006 and 2018 were included 
in the analysis. Follow-up ranged from 1 to 138 months. Data 
collection was finished five years after the treatment of 
the last patient included in the study had ended. Detailed 
analysis of known EC prognostic factors, comorbidity, bio-
chemical test results, type of surgery, its duration, extent 
and the hospital where it was performed, stage and grade of 
cancer, its histology and Bokhman type, the type of adjuvant 
treatment, and its outcome in RECIST criteria was performed. 
Progression free survival (PFS) and overall survival (OS) 
have been set as endpoints and assessed in periods of 12, 
36 and 60 months. The patients have not been differentiated 
by the cause of death due to insufficient data. 
Qualitative data was analysed by counting the number 
and percentage of each value. Comparison of those variables 
was made using chi-squared test or Fisher detailed test in 
case of groups with low expected quantity. Kaplan-Meier 
curves were used to demonstrate the results of the analyses 
of qualitative features, and their comparison was made using 
log-rank test. Quantitative data was analysed by counting 
the mean value, standard deviation, the median, quartiles, 
the minimal value and the maximal value. Comparison of 
those variables was made using Mann-Whitney test. In cases 
of three or more groups the comparison was made using 
Kruskal-Wallis test. Features which showed statistically sig-
nificant differences were analysed post-hoc with Dunn test. 
Cox proportional hazard ratio model was used to examine 
the influence of quantitative features on PFS and OS. The 
results have been shown using hazard ratio (HR) with 95% 
confidence interval. The cut-off values for tests based on 
quantitative data were determined using receiver operating 
characteristic (ROC) curves. Utility of a quantitative variable 
as a predictor was assessed using the area under the ROC 
curve (AUC). P value below 0.05 was set as the level of statisti-
cal significance. The analyses were made using R software.
RESULTS
The study group was comprised of 266 advanced endo-
metrial cancer patients. The youngest patient was 34, while 
the oldest was 91 years old at the time of the beginning of 
treatment. The average age was 65.5, and its median was 
66 years. 192 (72%) of patients had comorbidity, of which 
the most common was arterial hypertension (169 cases 
— 63.5%). Furthermore, there were cases of ischemic heart 
disease, arrhythmia, diabetes mellitus, hypo- and hyperthy-
roidism, asthma, chronic obturatory pulmonary disease, 
vascular lesions, thromboembolism and other. One hundred 
thirteen patients were obese and further 72 were over-
weight. FIGO stage IIIB accounted for 35% of cases, followed 
by IIIA — 28% and IIIC — 24%. Only 5% of patients were 
stage IV. There were 182 Bokhman type I EC cases, of which 
152 were of pure endometrioid histology, and the others had 
mucinous and planoepithelial components. Bokhman type 
II EC cases accounted for 26% (n = 70) of the group and were 
comprised of histological types such as: serous (n = 17), clear 
cell (n = 10), carcinosarcoma (n = 13) and mixed (n = 30). 
The detailed data is shown in Table 1.
Five-year overall survival rate in the study group was 
49,6%, and progression-free survival rate 45,4%. Median OS 
was 60 months, while half of the patients had progression 
after 50 months. Table 2 shows detailed data.
There was paucity of data on detailed CBC before treat-
ment, because in most treatment centres the neutrophil 
count and the lymphocyte count were not assessed before 
surgery. The CBC data collected before adjuvant treatment 
was far more complete and of better quality because most 
of the results came from a single laboratory in COOK. Sur-
vival analysis in the context of variables such as: age at the 
moment of diagnosis, BMI before treatment, WBC before 
surgery, and before adjuvant treatment (AT), PLT before 
surgery and before AT, NLR and PLR before AT, comorbidity, 
in particular DM and its treatment with metformin, FIGO 
stage, histologic grade, Bokhman type, depth of myometrial 
invasion has been performed. Results of the analysis for the 
variables which correlated significantly with PFS and/or OS 
are given in Table 3 and 4.
Afterwards ROC curves have been drawn for NLR and 
PLR. Area under curve (AUC) values were 0.608 for NLR and 
0,613 for PLR (Fig. 1). Optimal cut-off values for examined 
parameters have been assessed, equalling:
 Ū NLR = 3.88 — sensitivity 80.6% and specificity 42.39%
 Ū PLR = 231.3 — sensitivity 80.6% and specificity 42.39%.
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The results of a univariate analysis of the relation be-
tween dichotomised NLR and PLR values (high — above 
cut-off, low — below cut-off ) and OS and PFS are given 
in Table 5, and on Figure 2 and 3 for NLR and PLR respec-
tively. Due to the fact that both parameters presented 
statistically significant correlation with OS and PFS an at-
tempt to distinguish three risk groups based on their 
value has been made: LL — both values „low”, HH — both 
values „high”, LH — one value „low” and the other one 
„high”. The survival analysis in relation to subgroups has 
shown a significant correlation with both OS and PFS. 
Above-mentioned results are included in table 5 and 
presented on Figure 4.
A multivariate analysis of the prognostic value of NLR 
and PLR before AT was then conducted with inclusion of 
known significant prognostic factors such as age, histologic 
grade and Bokhman type. Due to similarity of NRL and PLR 
two separate analyses were done for each parameter alone. 
The results have shown that NRL was the only independent 
prognostic factor for both 5-year OS and PFS in the study 
group. Hazard ratios were similar for death and progression 
and equalled 2.6 in case of high NRL value. Detailed results 
of this analysis are presented in Table 6.
DISCUSSION
Neutrophils secrete an abundance of cytokines, 
growth factors and enzymes such as Il-6, Il-8, VEGF, HGF, 
metalproteinases and elastases, which take part in the 
creation of a tumour promoting microenvironment, by 
decomposition of the extracellular matrix, promotion of 
neoangiogenesis or inhibition of anti-cancer immune 
response — suppression of activated T-lymphocytes and 
natural killers. On the other hand, lymphocyte invasion 
into cancer tissue is frequently linked with better response 
to chemotherapy and thus better prognosis. NLR joins 
the neutrophil and the lymphocyte count into one clear 
parameter [16–19].
Table 1. Demographic and clinical characteristic of the study group
Demographic and clinical characteristic of the study group
Feature Mean (SD) Median (quartile)
Age [years]






30.13 (5.93) 29.8 (25.98–33.85)
Underweight (< 18.5) 1 0.4
Normal (18.5–25) 44 16.5
Overweight (25–30) 72 27.1
Obese (> 30) 113 42.5

















No data 22 8.27
Bokhman type
Type I 182 68.42
Type II 70 26.32





No data 49 18.42
SD — standard deviation; BMI — body mass index
Table 2. Overall survival and progression-free survival in the study group
Number of patients Number of events
Overall survival
12 months 36 months 60 months Median [months]
266 106 87.23% 59.54% 49.59% 60
Number of patients Number of events
Progression-free survival
12 months 36 months 60 months Median [months]
266 122 71.02% 53.14% 45.42% 50
Post-treatment follow-up [months]
N Mean SD Median Min Max Q1 Q3
266 36.94 31.63 25 1 138 11 61
SD — standard deviation
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A meta-analysis conducted by Templeton gives an over-
view of the results of 100 papers, which include 40,559 pa-
tients with solid tumours, to assess the prognostic value of 
NLR [20]. Diseases such as breast, colon, ovarian, cervical 
cancer or mesothelioma were included, among others. There 
were no cases of endometrial cancer in the analysis. Cut-off 
Table 3. Results of the analysis of selected variables in relation to overall survival
Results of the analysis of selected variables in relation to OS
N Variable Unit HR 95%CI p
1 Age at the moment of diagnosis years 1.035 1.013 1.056 0.001
2 PLT before surgery 103/μL 1.003 1 1.005 0.02
3 WBC before AT 103/μL 1.073 1.046 1.101 < 0.001
4 PLT before AT 103/μL 1.005 1.003 1.006 < 0.001
5 NLR 1.06 1.034 1.086 < 0.001
6 PLR 1.001 1 1.002 0.011





12 months 36 months 60 months Median [months]
7. Histologic grade
G1 34 8 93.21% 77.03% 64.19% > max obs.
p < 0.001G2 127 40 92.22% 71.65% 63.24% 116
G3 57 30 81.03% 37.82% 24.82% 25
8. Bokhman type
I 183 57 91.32% 69.08% 59.83% 116
p < 0.001
II 71 42 75.24% 40.53% 28.43% 25
OS — overall survival; HR — hazard ratio; CI — confidence interval; PLT — total platelet count; WBC — white blood count; AT — adjuvant therapy;  
NLR — neutrophil/lymphocyte ratio; PLR — platelet/lymphocyte ratio
Table 4. Results of the analysis of selected variables in relation to progression free survival
Results of the analysis of selected variables in relation to PFS
N Variable Unit HR 95%CI p
1 Age at the moment of diagnosis [years] 1.026 1.006 1.046 0.009
2 PLT before surgery 103/μL 1.003 1 1.005 0.027
3 LEU before AT 103/μL 1.064 1.043 1.085 < 0.001
4 PLT before AT 103/μL 1.004 1.003 1.005 < 0.001
5 NLR 1.054 1.03 1.078 < 0.001
6 PLR 1.001 1 1.002 0.036





12 months 36 months 60 months Median [months]
7. Histologic grade
G1 34 10 80.40% 73.09% 63.34% > max obs.
p < 0.001G2 127 47 82.92% 65.18% 57.61% 93
G3I 57 34 52.86% 27.11% 23.24% 15
8. Bokhman type
I 183 68 80.24% 62.69% 55.13% 93
p < 0.001
II 71 46 48.74% 32.63% 24.16% 12
9. Depth of myometrial invasion
< 1/2 39 10 88.89% 75.00% 71.43% > max obs.
p = 0.018
> 1/2 163 69 80.54% 58.59% 47.84% 58
PFS — progression free survival; HR — hazard ratio; CI — confidence interval; PLT — total platelet count; WBC — white blood count; AT — adjuvant therapy;  
NLR — neutrophil/lymphocyte ratio; PLR — platelet/lymphocyte ratio
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Table 5. Prognostic value analysis of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio as qualitative variables in relation to overall 
survival and progression free survival
Prognostic value analysis of NLR and PLR as qualitative variables in relation to OS (1–3) and PFS (4–6)
Variable Number of patients




12 months 36 months 60 months Median [months]
1. NLR low (L) / high (H) — OS
L 155 58 89.53% 64.98% 56.67% 116
p = 0.005
H 83 39 83.04% 48.29% 36.35% 35
2. PLR low (L)/high (H) — OS
L 158 57 89.66% 65.96% 57.37% 116
p = 0.001
H 80 40 82.67% 46.12% 35.37% 28
3. Groups NLR + PLR — OS
LL 135 48 90.39% 67.46% 58.87% 116
p = 0.002LH/HL 43 19 84.44% 52.06% 44.86% 42
HH 60 30 82.26% 45.55% 32.57% 26
4. NLR low (L)/high (H) — PFS
L 155 69 76.93% 58.58% 50.16% 63
p = 0.008
H 83 44 54.06% 41.26% 36.25% 18
5. PLR low (L) / high (H) — PFS
L 158 69 74.63% 60.40% 50.90% 63
p = 0.006
H 80 44 58.17% 35.90% 33.66% 21
6. Groups NLR + PLR — PFS
LL 135 58 77.41% 61.67% 51.93% 93
p = 0.008LH/HL 43 22 65.29% 45.42% 41.93% 26
HH 60 33 52.29% 36.02% 32.42% 16
OS — overall survival; PFS — progression free survival; NLR — neutrophil/lymphocyte ratio; PLR — platelet/lymphocyte ratio
Figure 1. Kapplan-Meier overall survival and progression free survival 
curves for neutrophil/lymphocyte ratio (NLR)
Figure 3. Kapplan-Meier overall survival and progression free survival 
curves for platelet/lymphocyte ratio (PLR)
Figure 4. Kapplan-Meier overall survival and progression free survival 
curves for neutrophil/lymphocyte ratio (NLR)/platelet/lymphocyte 
ratio (PLR)  — L/H.
Figure 2. Receiver operating characteristic curves for neutrophil/ 
/lymphocyte ratio (NLR) (left) and platelet/lymphocyte ratio (PLR) 
(right); AUC — area under curve
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values for NLR ranged from 3.0 to 5.0, the latter one being the 
most common (33%). A marginally significant relation be-
tween cut-off values and hazard ratios was observed. There 
was a statistically significant correlation between NRL value 
and overall survival (HR = 1.81), which was also observed 
in relation to cancer specific survival (CSS), progression-free 
survival and disease-free survival (DFS). The strength of the 
correlation was bigger in cases of metastatic disease than in 
those confined to the primary tumour site. HR for metastatic 
cancer equalled 1.8 (1.63–1.99), and 1.57 (1.36–1.82) when 
there were no metastases. The authors explain that effect 
with bigger tumour burden or longer-lasting cancer-related 
inflammation in advanced cases [25].
The amount of papers on NLR in endometrial cancer is 
scarce. A meta-analysis conducted by Ethier on the prognos-
tic value of NRL in gynaecological cancers includes only five 
studies concerning EC, three of which assessed only OS, and 
two where PFS was also taken into account. It has been no-
ticed that in studies where five year survival was lower the NLR 
cut-offs tended to be set higher. No relation between most 
known clinic-pathologic prognostic factors and NLR was 
found, with the exception of histologic grade — G3. In cases 
of G3 endometrial cancer the correlation was stronger [21]. 
Haruma and al. made a retrospective analysis of 320 cases 
of EC. The study group was comprised of 253 FIGO stage 
I–II patients and 67 FIGO stage III-IV patients. There were 
276 cases of Bokhman type I EC (of which 40 were G3), and 
46 type II. NLR and PLR measurements were taken in the 
month preceding surgery. NLR was found to be dependent 
on stage (FIGO I-II vs III-IV), histology (G1–2 vs G3 + type II EC) 
and myometrial invasion. Cut-off values were set as 2.7 for 
OS and 2.41 for DFS. In multivariate analysis only NLR and 
“histology” were determined to be independent prognostic 
factors [26]. Currently the biggest study concerning NRL 
in endometrial cancer was conducted by Cummings. It is 
a retrospective analysis of 733 EC patients in all stages, 
of which 78% were FIGO I–II. The authors examined the prog-
nostic value of NLR, PLR and monocyte-lymphocyte ratio 
(MLR) measured before operative treatment. The optimal 
cut-off value for NLR was set to 2.4 in this study. A statistically 
significant correlation between NLR and OS as well as CSS 
was found in univariate analysis. In the multivariate analysis 
including variables such as age, stage, grade, Bokhman type 
and LVSI invasion, NLR was determined to be an independ-
ent prognostic factor [15].
As opposed to the above-mentioned papers, this study 
is focused solely on the advanced EC patients — FIGO 
stages III–IV, and the NRL and PLR values have not been 
measured before surgery but at the stage of adjuvant 
treatment planning. The results of the univariate analysis 
indicate a statistically significant correlation between the 
value of NLR and 5-year OS — HR = 1.06 (p < 0.001) and 
PFS — HR = 1.054 (p < 0.001). The mean NLR value in the 
study group was 4.2 [standard deviation (SD) 6.43], and its 
median 3.13. An optimal cut-off value of 3.88 has been set 
using the ROC curve analysis. Five year overall survival was 
57% and 36% for low and high NLR accordingly. No rela-
tion between NLR and Bokhman type, histologic grade or 
surgical radicality was found. The results of a multivariate 
analysis including age, histologic grade and Bokhman type 
have shown that NLR is the only independent prognostic 
factor of OS (HR = 2.6), as well as of PFS (HR = 2.6) in this 
study group. Hazard ratio values obtained in the univariate 
analysis are lower than in the cited papers which may be 
due to a smaller tumour burden after surgery, that may 
implicate a weaker cancer-related immune response. Such 
an explanation was suggested in the Templeton meta-anal-
ysis. It is important to notice that the set NLR cut-off value 
(3.88) was considerably different than those in Cummings 
and Haruma studies (2.4, 2.7), and were closer to those 
observed by Templeton in cases of advanced or metastatic 
cancer (4–5).
Platelets take part in the tumour promoting inflamma-
tory response. One of the essential elements of the process 
is Il-6 which promotes megakaryocyte differentiation into 
platelets by stimulating the production of thrombopoietin. 
High level of Il-6 was proven to be an independent prognos-
Table 6. Multivariate analysis results — neutrophil/lymphocyte ratio
Multivariate analysis including NLR
Feature HR 95%CI p
OS
Age [years] 1.03 0.998 1.062 0.064
Grade
G1 1 ref.
G2 1.012 0.364 2.815 0.982




II 1.523 0.693 3.347 0.295
NLR
Low 1 ref.
High 2.589 1.281 5.235 0.008
PFS
Age [years] 1.026 0.997 1.057 0.084
Grade
GI 1 ref.
GII 1.291 0.524 3.183 0.578




II 1.661 0.796 3.467 0.177
NLR
Low 1 ref.
High 2.597 1.389 4.852 0.003
OS — overall survival; PFS — progression free survival;  
NLR — neutrophil/lymphocyte ratio
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tic factor of bad outcome in ovarian cancer. Its reflection in 
CBC might be high platelet count. PLR is a parameter derived 
from CBC, which takes into account the platelet count as 
well as the lymphocyte count [5, 22, 23].
One of the most comprehensive studies on the prog-
nostic value of PLR in solid tumours is a 2014 meta-anal-
ysis conducted by Templeton. It includes 12,890 patients 
from 22 different studies, who were diagnosed with such 
malignancies as mesothelioma, pancreatic, breast or ovar-
ian cancer among others. It does not include any studies 
concerning endometrial cancer. The authors point out that 
a significant prognostic value of PLR is observed especially 
with advanced cancer. In studies where the disease was 
confined to the primary site the effect was rarely seen or 
marginal. The determined optimal cut-off values ranged 
from 150 to 300 depending on the type of cancer and its 
stage, and in most cases were higher in the metastatic dis-
ease. The authors conclude that the prognostic value of PLR 
is strongly dependent on the stage of cancer, and it tends 
to be higher in more advanced stages [24].
The number of papers regarding PLR in EC is scant. The 
Haruma study quoted before is one of the two major studies 
relating to PLR in endometrial cancer. The results indicate 
that similarly to NLR also PLR was influenced by stage, „his-
tology” and depth of myometrial invasion. The prognostic 
value of PLR was proven to be statistically significant in 
terms of OS and DFS only in the univariate analysis. The 
determined cut-off value was 175. The authors conclude 
that PLR is a weaker prognostic factor than NLR [26]. The 
second of the major studies, by Cummings, was also referred 
to previously in the context of NLR. The cut-off value set by 
the authors for PLR was 240. The results of the univariate 
analysis have shown a significant correlation between PRL 
and OS as well as CSS. The outcome of multivariate analysis, 
which included age, stage, histologic grade, Bokhman type, 
and LVSI status indicated PLR as an independent prognostic 
factor. It was also shown that the value of PRL is related 
significantly to age, stage, nodal involvement and LVSI sta-
tus. The authors have distinguished three prognostic groups 
based on the PLR and NLR values, which differed in OS and 
CSS in a statistically significant way [15].
The results of Cox proportional hazard analysis in our 
group of aEC patients indicate that the correlation be-
tween PLR and 5-year OS (HR = 1.001; p = 0.011) and PFS 
(HR = 1.001; p = 0.011) is statistically significant in the uni-
variate analysis. The hazard ratio value is low because of 
the small unitary value of the parameter — the mean value 
was 237, and the standard deviation was 178 in the study 
group. The determined optimal cut-off value was 231.3 (sen-
sitivity 80.6%; specificity 42.4%). When dichotomised, the 
parameter allowed the formation of two groups differing 
significantly in terms of 5-year OS (L — 57.4%; H —35.4%) 
and PFS (L — 50.9%; H — 33.6%). Similarly to NLR there was 
no significant relation between PLR and histologic type, 
grade and surgical radicality. The outcome of a multivariate 
analysis indicated that PLR is not an independent prognostic 
factor of neither OS nor PFS in aEC. The cut-off values which 
were defined as optimal in our analysis were similar to those 
in the paper by Cummings et al.
What has to be pointed out is that due to the low speci-
ficity of the dichotomised NLR and PLR some patients might 
be misclassified, so the cut-off values should be reassessed 
in a better designed, preferably prospective study.
The outcome of stratification of our group of aEC pa-
tients to three risk groups, based on the NLR and PLR status 
met our expectations. The 5-year OS in the low-risk group 
was 59% in comparison to 33% in the high-risk group. The 
differences were statistically significant. The proposed di-
vision may provide an additional argument in the deci-
sion-making process while planning individual adjuvant 
treatment for advanced endometrial cancer patients.
CONCLUSIONS
Both NLR and PLR measured before adjuvant treatment 
were found to have significant prognostic value in relation to 
OS and PFS among advanced endometrial cancer patients, 
while in the multivariate analysis NLR was found to be an in-
dependent prognostic factor of OS as well as PFS. Taking into 
account the fact that the determination of those parameters 
is cost neutral, they may be easily taken into consideration in 
the decision-making process while planning individualised 
adjuvant treatment for aEC patients. Further prospective 
studies should be carried out for better determination of 
their prognostic value and optimal cut-off points in aEC.
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